News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

University College London, Moorfields Eye Hospital and Targeted Genetics Corporation (TGEN) Initiate Phase I/II Clinical Trial of Gene Therapy for Childhood Blindness



5/1/2007 10:45:06 AM

LONDON and SEATTLE, WA -- (MARKET WIRE) -- May 01, 2007 -- University College London's (UCL) Institute of Ophthalmology, Moorfields Eye Hospital and Targeted Genetics Corporation (NASDAQ: TGEN) today announced the initiation of a Phase I/II clinical trial to test an innovative approach to treating a form of childhood blindness. The trial, funded by the UK Department of Health is the first of its kind and could have a significant impact on future treatments for eye disease.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES